Clinical trials: Atopic Hypersensitivity
Eczema
Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin
The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC) skin balm in infants and toddlers with mild to moderate dry, itchy skin.
- Trial name
- NCT02404493
- Testing
- EpiCeram Skin Barrier Emulsion, 1% Colloidal Oatmeal Balm
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
The primary objectives of this study are to: estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 estimate vaccine response in rocatinlimab group vs placebo…
- Trial name
- ROCKET-VOYAGER (NCT05899816)
- Testing
- Rocatinlimab
- Where
- 85 sites in United States, Canada
- Volunteers
- 221 people
- Sponsor
- Amgen
Atopic Dermatitis
LEO 29102 Cream in the Treatment of Atopic Dermatitis
This is a proof of concept and dose finding Phase II trial comparing 5 dose strengths with vehicle and an active comparator (Elidel cream 10 mg/g) in a 4 week, twice daily treatment regimen in mild to moderate atopic dermatitis…
- Trial name
- NCT01037881
- Testing
- LEO 29102, Elidel®
- Where
- 3 sites in Canada, Finland and 1 more
- Volunteers
- 183 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03363854
- Testing
- Tralokinumab
- Where
- 66 sites in United States, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- LEO Pharma
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Eczema, Dermatitis
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)
This is an efficacy and safety study of up to 12 weeks of desloratadine in Japanese participants with eczema/dermatitis and dermal pruritus.
- Conditions
- Eczema, Dermatitis, Dermal Pruritus
- Trial name
- NCT01916980
- Testing
- Desloratadine 5 mg
- Volunteers
- 94 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in…
- Trial name
- NCT03908970
- Testing
- 1% OPA-15406
- Where
- Japan
- Volunteers
- 364 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric Patients
The scope of this multicenter, double blind, randomized, vehicle-controlled clinical investigation is to evaluate and confirm the performance and safety of the Relizema cream in the improvement of the dermatitis severity in…
- Trial name
- YOUNG (NCT05259774)
- Testing
- Relizema cram
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
The purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (Vanos®) in the treatment of atopic dermatitis (AD).
- Trial name
- NCT01469767
- Testing
- Fluocinonide cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University
Atopic Dermatitis
A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in…
- Trial name
- Shaperon (NCT03492398)
- Testing
- HY209
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Shaperon
Eczema, Atopic Dermatitis
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis…
- Trial name
- NCT03775434
- Testing
- Experimental: B244
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- AOBiome LLC
Dermatitis, Atopic
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
- Trial name
- NCT05450198
- Testing
- MK-6194
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Dermatitis, Atopic
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to <12 years of age with severe atopic dermatitis (AD).
- Trial name
- NCT03345914
- Testing
- Dupilumab, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 367 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADmIRe (NCT03831191)
- Testing
- LY3375880
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 136 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine…
- Trial name
- BREEZE-AD4 (NCT03428100)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 103 sites in Austria, Belgium and 12 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Targeted Investigation of Microbiome Elimination
The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.
- Trial name
- TIME-1 (NCT05177328)
- Testing
- S. hominis A 9 Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis ([AD]; skin rash, inflammation) that is…
- Trial name
- NCT00455429
- Testing
- JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily
- Where
- 19 sites in United States
- Volunteers
- 84 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT02595008
- Testing
- DSXS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.